something strange happening here. they are still refusing to let Jack Cowin conduct due diligence so he can possibly make an alternative bid. At 70 cents it is still way too cheap.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%